Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Enrollment open in phase Ib/II study of KRT-232 with acalabrutinib in DLBCL and CLL

Dec. 9, 2020

Jacobio initiates first-in-human study of JAB-8263 in advanced solid tumors

Dec. 9, 2020

Nuvation conducts phase I/II study of NUV-422 in recurrent or refractory high-grade gliomas

Dec. 9, 2020

New vulnerability in "KL" KRAS subtype

Dec. 7, 2020

Data from phase II studies of VAL-083 in glioblastoma

Dec. 7, 2020

New IDO-1 inhibitors synthesized at Hutchison MediPharma

Dec. 7, 2020

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent RET inhibitors

Dec. 7, 2020

Ascentawits Pharmaceuticals discovers AKR1C3-activatable DNA alkylating drugs

Dec. 7, 2020

New MAPK 1 inhibitors identified at Medshine Discovery

Dec. 7, 2020

Phase III study of masitinib in first-line pancreatic cancer with pain shows survival increase

Dec. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Combination locked out in ATTR-CM? ‘Dead,’ expert says
BioWorld
The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the...